Opioid Abuse Clinical Trial
Official title:
Medications Development for Drug Abuse Disorders
This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to other drugs like stimulants. The doses of tramadol used in this study are higher than those generally used for the treatment of pain. To be in this study a participant must be a user of opioids (drugs like heroin) and stimulants (drugs like cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and generally healthy. Up to 12 people will take part in this study.
This is a human laboratory study that tests the effects of tramadol as a step in the possible
development of this medication as a new treatment for opioid dependence. Tramadol is a
mild/moderate mu agonist opioid currently marketed as an analgesic that has a unique profile
of effects. One of the primary metabolites of tramadol, mono-O-demethyltramadol (referred to
as M1) exerts opioid agonist effects at the mu receptor. In addition, tramadol and M1 produce
reuptake blockade of monoamines, and this latter effect may positively influence its
analgesic efficacy, in addition to influencing the subjective effects produced by tramadol.
Preclinical evidence suggests that tramadol's effects on monoamine reuptake may have
antidepressant qualities as well. Given tramadol's diverse pharmacodynamic profile, a
systematic characterization of its subjective effects in opioid-experienced subjects would
provide valuable information regarding its abuse liability, and its potential utility as a
treatment for opioid dependence.
The characterization of an opioid medication's profile can be accomplished through a variety
of experimental procedures. One useful procedure for assessing the profile of an opioid is a
drug discrimination procedure. In this methodology, subjects are first trained to
discriminate reference drugs such as placebo and an opioid agonist, and then administered
doses of a novel compound to determine how like (or unlike) it is to the reference training
conditions. Our laboratory has a long history of using this drug discrimination methodology
to study and to characterize opioids with varying opioid receptor activity profiles. Studies
have generally included either two or three training conditions in humans. Using this
technique in volunteers, studies have characterized the profile of a number of opioids
including (for example) butorphanol, nalbuphine, pentazocine, and buprenorphine.
While most of these studies testing the effects of mixed agonist-antagonist opioids have used
an opioid agonist and placebo as the training conditions, tramadol's profile of effects
suggests that there may be a non-opioid component of action at serotonin and norepinephrine
sites that will be useful to distinguish. In particular, it is of interest to determine the
extent to which tramadol is identified as being like a prototypic mu agonist opioid, whether
it is substantially identified as being like a non-opioid compound, and if this non-opioid
component is related to enhancement of monoamine effects. In order to provide a meaningful
non-opioid contrast training condition, this study will compare different doses of tramadol
to training conditions of placebo, a mu agonist opioid, and a prototypic stimulant.
Overall, this evaluation will provide a greater understanding of the subjective effect
profile of tramadol in comparison to a prototypic mu opioid and a prototypic stimulant. If
tramadol is to be useful in the treatment of opioid dependence, a thorough assessment of its
subjective effects in experienced opioid and stimulant abusers is warranted.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04839978 -
Community Trial in the Cherokee Nation
|
N/A | |
Completed |
NCT05593341 -
Opioid Education in Total Knee Arthroplasty
|
N/A | |
Terminated |
NCT04495374 -
Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy
|
Phase 4 | |
Terminated |
NCT03822962 -
Pain Management Following Sinus Surgery
|
Early Phase 1 | |
Completed |
NCT03936985 -
Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
|
||
Active, not recruiting |
NCT01740414 -
Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
|
Phase 2 | |
Completed |
NCT03684681 -
The Navigator Trial
|
N/A | |
Completed |
NCT04340622 -
Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders
|
N/A | |
Completed |
NCT04018664 -
Oral Abuse Potential Study of Nalbuphine
|
Phase 1 | |
Completed |
NCT00699010 -
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
|
Phase 2 | |
Recruiting |
NCT05006079 -
Opioid/Benzodiazepine Polydrug Abuse: Aim 3
|
Phase 2 | |
Completed |
NCT04710069 -
Postoperative Opt-In Narcotic Treatment Study
|
N/A | |
Terminated |
NCT03992079 -
A Multimodal Enhanced Recovery Program in Anorectal Surgery
|
N/A | |
Active, not recruiting |
NCT03570099 -
Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications
|
||
Completed |
NCT02804152 -
Program for Pain & Prescription Opioid Use in Pregnancy
|
N/A | |
Active, not recruiting |
NCT01632982 -
Mobile Psychosocial Interventions for MMT Clients
|
N/A | |
Active, not recruiting |
NCT01136356 -
A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05706311 -
Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool
|
N/A | |
Completed |
NCT03743493 -
PCORnet Opioid Surveillance Study
|
||
Completed |
NCT03143855 -
Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
|
Phase 1 |